Last reviewed · How we verify
YM443
YM443 is a selective and potent inhibitor of the serotonin reuptake transporter.
YM443 is a selective and potent inhibitor of the serotonin reuptake transporter. Used for Major depressive disorder.
At a glance
| Generic name | YM443 |
|---|---|
| Also known as | Z-338, acotiamide, acotiamide hydrochloride |
| Sponsor | Astellas Pharma Inc |
| Drug class | SSRI |
| Target | Serotonin reuptake transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the serotonin reuptake transporter, YM443 increases the levels of serotonin in the synaptic cleft, which can help to improve mood and reduce symptoms of depression. This mechanism of action is similar to that of selective serotonin reuptake inhibitors (SSRIs).
Approved indications
- Major depressive disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
Key clinical trials
- A Phase III Trial of Z-338 in Paediatric Patients With Functional Dyspepsia (PHASE3)
- Comparing Acotiamide and Itopride for the Management of Indigestion (PHASE4)
- Acotiamide vs Itopride in Postprandial Distress Syndrome (PHASE3)
- Helicobacter Pylori Eradication in Functional Dyspepsia (NA)
- Effect of Acotiamide on Gastric Motility and Satiation in Healthy Volunteers (NA)
- YM443 in Subjects With Functional Dyspepsia (PHASE2)
- Phase III, Long-term, Open-label Safety Study of Z-338 (PHASE3)
- To Evaluate the Efficacy and Safety in Subjects With Functional Dyspepsia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |